These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29844042)

  • 1. Lipopeptide Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against Carbapenem-Resistant Pathogens.
    Moon SH; Huang E
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatically-crosslinked gelatin hydrogels containing paenipeptin and clarithromycin against carbapenem-resistant pathogen in murine skin wound infection.
    Moon SH; Kaufmann Y; Fujiwara R; Huang E
    BMC Microbiol; 2021 Nov; 21(1):326. PubMed ID: 34819026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.
    Moon SH; Zhang X; Zheng G; Meeker DG; Smeltzer MS; Huang E
    J Med Chem; 2017 Dec; 60(23):9630-9640. PubMed ID: 29136469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against
    Moon SH; Kaufmann Y; Huang E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
    Clock SA; Tabibi S; Alba L; Kubin CJ; Whittier S; Saiman L
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):343-6. PubMed ID: 23601454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii.
    Wan G; Ruan L; Yin Y; Yang T; Ge M; Cheng X
    Int J Nanomedicine; 2016; 11():3789-800. PubMed ID: 27574420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
    Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of tigecycline against multiple resistant Acinetobacter baumannii and carbapenem resistant Klebsiella pneumoniae isolates].
    Arikan Akan O; Uysal S
    Mikrobiyol Bul; 2008 Apr; 42(2):209-15. PubMed ID: 18697418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
    Yadav R; Landersdorfer CB; Nation RL; Boyce JD; Bulitta JB
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates.
    Zhang Y; Li P; Yin Y; Li F; Zhang Q
    J Antibiot (Tokyo); 2017 Feb; 70(2):193-195. PubMed ID: 27460764
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
    García-Salguero C; Rodríguez-Avial I; Picazo JJ; Culebras E
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5959-66. PubMed ID: 26169398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin.
    Vaara M; Siikanen O; Apajalahti J; Frimodt-Møller N; Vaara T
    J Antimicrob Chemother; 2010 May; 65(5):942-5. PubMed ID: 20167589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
    Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
    J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U; Chatsuwan T
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.